XLVIvsRSPHETF Comparison
ETF 1
XLVI
State Street Health Care Select Sector SPDR Premium Income Fund
This fund is part of
Options Strategies
-0.49%
VS
State Street Health Care Select Sector SPDR Premium Income Fund (XLVI) belongs to the Options Strategies segment. Invesco S&P 500® Equal Weight Health Care ETF (RSPH) is part of the US Health Care segment. Both ETFs have the same top 2 sector exposures: Healthcare and Consumer Non-Cyclicals. XLVI is less expensive with a Total Expense Ratio (TER) of 0.35%, versus 0.4% for RSPH. XLVI is up 5.69% year-to-date (YTD) with +$14M in YTD flows. RSPH performs better with 13.31% YTD performance, and -$2M in YTD flows. Run a side-by-side ETF comparison of XLVI and RSPH below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
XLVI vs RSPH performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 09/10/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | XLVI RSPH | -3.75%-0.16% | +3.97%+12.90% | +5.69%+13.31% | +16.54%+24.71% | n/a+29.20% | n/a+18.61% |
| Flows | XLVI RSPH | +$4M+$42M | +$11M+$89M | +$14M-$2M | +$25M-$22M | --$316M | --$272M |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | XLVI RSPH | +11.87%+20.83% | +11.09%+16.91% | n/a+15.88% | n/a+16.79% |
| Max drawdown | XLVI RSPH | -4.77%-5.57% | -8.21%-10.87% | n/a-16.96% | n/a-21.91% |
| Max drawdown duration | XLVI RSPH | 16d22d | 115d116d | n/a434d | n/a817d |
Trading data
XLVI | RSPH | |
Last sale 9/11/2026 at 1:30 PM | $25.71 | $36.08 |
| Previous close 09/10/2026 | $25.73 | $35.92 |
| Consolidated volume 09/10/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Replication quality
Data as of August 31, 2026
1-year trailing difference
Create an account to view replication metrics
Join for free
XLVI
is actively managed and doesn’t replicate an indexXLVI | RSPH | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
Advertisement
Main metrics
Last update 9/11/2026 at 1:30 PM
Live
Closed
XLVI | RSPH | |
|---|---|---|
| Last price | $25.71 | $36.08 |
| 1D performance | -0.07% | +0.45% |
| AuM | $25.47 M | $831.15 M |
| E/R | 0.35% | 0.4% |
Characteristics
XLVI | RSPH | |
|---|---|---|
| Management strategy | Active | Passive |
| Provider | State Street Investment Management | Invesco |
| Benchmark | - | S&P 500 Equal Weight Health Care Index |
| N° of holdings | 59 | 59 |
| Asset class | - | Equities |
| Trailing 12m distribution yield | Join | Join |
| Inception date | July 30, 2025 | November 1, 2006 |
| ESG | No | No |
Advertisement
Exposure
Countries
XLVI
USA
97.34%
Other
2.66%
RSPH
USA
96.6%
Other
3.4%
Sectors
XLVI
Healthcare
97.32%
Other
2.68%
RSPH
Healthcare
98.34%
Other
1.66%
Advertisement
Diversification
XLVI
Total weight of top 15 holdings out of 15
71.63%
RSPH
Total weight of top 15 holdings out of 15
28.14%
Top 15 holdings
Data as of July 31, 2026
XLVI
Eli Lilly & Co.
15.45%
Johnson & Johnson
10.49%
AbbVie, Inc.
7.54%
UnitedHealth Group, Inc.
6.40%
Merck & Co., Inc.
5.47%
Thermo Fisher Scientific, Inc.
3.63%
Amgen, Inc.
3.53%
Abbott Laboratories
3.13%
Gilead Sciences, Inc.
2.75%
Pfizer Inc.
2.42%
Bristol Myers Squibb Co.
2.27%
CVS Health Corp.
2.27%
Intuitive Surgical, Inc.
2.13%
Danaher Corp.
2.09%
Vertex Pharmaceuticals, Inc.
2.06%
RSPH
Bio-Techne Corp.
2.10%
IQVIA Holdings, Inc.
2.08%
Veeva Systems, Inc.
1.95%
Charles River Laboratories International, Inc.
1.93%
Mettler-Toledo International, Inc.
1.89%
Baxter International, Inc.
1.87%
DaVita, Inc.
1.86%
Abbott Laboratories
1.86%
Incyte Corp.
1.85%
Thermo Fisher Scientific, Inc.
1.83%
Moderna, Inc.
1.82%
AbbVie, Inc.
1.79%
Universal Health Services, Inc.
1.78%
Regeneron Pharmaceuticals, Inc.
1.77%
Quest Diagnostics, Inc.
1.77%
Frequently asked questions about XLVI and RSPH
How have the XLVI and RSPH ETFs performed in 2026?
As of September 10, 2026, XLVI is up 5.69% year-to-date (YTD), while RSPH has returned 13.31%. That puts RSPH better performer ahead so far this year.
Which ETF is attracting more investor money: XLVI or RSPH?
Year-to-date, the XLVI ETF saw +$14M in flows, compared to -$2M for RSPH.
Which ETF is more volatile: XLVI or RSPH?
Over the past year, XLVI had a volatility of 11.09%, while RSPH experienced 16.91%.
Which ETF is bigger: XLVI or RSPH?
As of September 10, 2026, XLVI holds $25.47 M in assets under management (AUM), while RSPH manages $831.15 M.
What sectors do the XLVI and RSPH ETFs invest in?
XLVI leans toward sectors like Healthcare. Meanwhile, RSPH focuses on Healthcare.
What are the top holdings of the XLVI ETF and RSPH ETF?
XLVI top holdings include Eli Lilly & Co., Johnson & Johnson and AbbVie, Inc.. RSPH holds in its top three: Bio-Techne Corp., IQVIA Holdings, Inc. and Veeva Systems, Inc..
Which ETF is more diversified: XLVI or RSPH?
XLVI holds 59 securities with 71.63% of its assets in the top 15. RSPH has 59 securities and a top 15 weight of 28.14%.
Advertisement
Latest news about XLVI & RSPH
Advertisement
